Rate of vision loss in neovascular age-related macular degeneration explored
- Autores
- Real, Juan Pablo; Granero, Gladys Ester; de Santis, Mariana Olga; Juarez, Claudio P.; Palma, Santiago Daniel; Kelly, Simon P.; Luna, José Domingo
- Año de publicación
- 2015
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Purpose: To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods: Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. Results: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis. The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Conclusion: Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss.
Fil: Real, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Granero, Gladys Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas. Departamento de Economía y Finanzas; Argentina
Fil: Juarez, Claudio P.. Centro Privado de Ojos Romagosa; Argentina
Fil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Kelly, Simon P.. Royal Bolton Hospital; Reino Unido
Fil: Luna, José Domingo. Centro Privado de Ojos Romagosa; Argentina - Materia
-
AGE-RELATED MACULAR DEGENERATION
BEVACIZUMAB
DISEASE PROGRESSION
HEALTH SYSTEMS
PATIENT SAFETY
RANIBIZUMAB - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/185832
Ver los metadatos del registro completo
id |
CONICETDig_b29f3194e43babe12d533cd2051bd6d5 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/185832 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Rate of vision loss in neovascular age-related macular degeneration exploredReal, Juan PabloGranero, Gladys Esterde Santis, Mariana OlgaJuarez, Claudio P.Palma, Santiago DanielKelly, Simon P.Luna, José DomingoAGE-RELATED MACULAR DEGENERATIONBEVACIZUMABDISEASE PROGRESSIONHEALTH SYSTEMSPATIENT SAFETYRANIBIZUMABhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Purpose: To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods: Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. Results: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis. The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Conclusion: Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss.Fil: Real, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: Granero, Gladys Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas. Departamento de Economía y Finanzas; ArgentinaFil: Juarez, Claudio P.. Centro Privado de Ojos Romagosa; ArgentinaFil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: Kelly, Simon P.. Royal Bolton Hospital; Reino UnidoFil: Luna, José Domingo. Centro Privado de Ojos Romagosa; ArgentinaSpringer2015-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/185832Real, Juan Pablo; Granero, Gladys Ester; de Santis, Mariana Olga; Juarez, Claudio P.; Palma, Santiago Daniel; et al.; Rate of vision loss in neovascular age-related macular degeneration explored; Springer; Graefes Archive For Clinical And Experimental Ophthalmology; 253; 11; 11-2015; 1859-18650721-832X1435-702XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s00417-014-2885-yinfo:eu-repo/semantics/altIdentifier/doi/10.1007/s00417-014-2885-yinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:56:51Zoai:ri.conicet.gov.ar:11336/185832instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:56:51.63CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Rate of vision loss in neovascular age-related macular degeneration explored |
title |
Rate of vision loss in neovascular age-related macular degeneration explored |
spellingShingle |
Rate of vision loss in neovascular age-related macular degeneration explored Real, Juan Pablo AGE-RELATED MACULAR DEGENERATION BEVACIZUMAB DISEASE PROGRESSION HEALTH SYSTEMS PATIENT SAFETY RANIBIZUMAB |
title_short |
Rate of vision loss in neovascular age-related macular degeneration explored |
title_full |
Rate of vision loss in neovascular age-related macular degeneration explored |
title_fullStr |
Rate of vision loss in neovascular age-related macular degeneration explored |
title_full_unstemmed |
Rate of vision loss in neovascular age-related macular degeneration explored |
title_sort |
Rate of vision loss in neovascular age-related macular degeneration explored |
dc.creator.none.fl_str_mv |
Real, Juan Pablo Granero, Gladys Ester de Santis, Mariana Olga Juarez, Claudio P. Palma, Santiago Daniel Kelly, Simon P. Luna, José Domingo |
author |
Real, Juan Pablo |
author_facet |
Real, Juan Pablo Granero, Gladys Ester de Santis, Mariana Olga Juarez, Claudio P. Palma, Santiago Daniel Kelly, Simon P. Luna, José Domingo |
author_role |
author |
author2 |
Granero, Gladys Ester de Santis, Mariana Olga Juarez, Claudio P. Palma, Santiago Daniel Kelly, Simon P. Luna, José Domingo |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
AGE-RELATED MACULAR DEGENERATION BEVACIZUMAB DISEASE PROGRESSION HEALTH SYSTEMS PATIENT SAFETY RANIBIZUMAB |
topic |
AGE-RELATED MACULAR DEGENERATION BEVACIZUMAB DISEASE PROGRESSION HEALTH SYSTEMS PATIENT SAFETY RANIBIZUMAB |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Purpose: To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods: Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. Results: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis. The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Conclusion: Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss. Fil: Real, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina Fil: Granero, Gladys Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina Fil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas. Departamento de Economía y Finanzas; Argentina Fil: Juarez, Claudio P.. Centro Privado de Ojos Romagosa; Argentina Fil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina Fil: Kelly, Simon P.. Royal Bolton Hospital; Reino Unido Fil: Luna, José Domingo. Centro Privado de Ojos Romagosa; Argentina |
description |
Purpose: To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods: Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted. Results: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the vision loss (R2 = 0.55 p < 0.01) and the less improvement following treatment (Pearson coefficient −0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis. The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. Conclusion: Visual loss awaiting injection intravitreal anti-VEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-11 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/185832 Real, Juan Pablo; Granero, Gladys Ester; de Santis, Mariana Olga; Juarez, Claudio P.; Palma, Santiago Daniel; et al.; Rate of vision loss in neovascular age-related macular degeneration explored; Springer; Graefes Archive For Clinical And Experimental Ophthalmology; 253; 11; 11-2015; 1859-1865 0721-832X 1435-702X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/185832 |
identifier_str_mv |
Real, Juan Pablo; Granero, Gladys Ester; de Santis, Mariana Olga; Juarez, Claudio P.; Palma, Santiago Daniel; et al.; Rate of vision loss in neovascular age-related macular degeneration explored; Springer; Graefes Archive For Clinical And Experimental Ophthalmology; 253; 11; 11-2015; 1859-1865 0721-832X 1435-702X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s00417-014-2885-y info:eu-repo/semantics/altIdentifier/doi/10.1007/s00417-014-2885-y |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Springer |
publisher.none.fl_str_mv |
Springer |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613705191391232 |
score |
13.070432 |